Published in ISRN Endocrinol on March 07, 2012
"Adjuvant Radioactive iodine 133 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience". J Otolaryngol Head Neck Surg (2015) 1.39
Prognosis of multifocal papillary thyroid carcinoma. Int J Endocrinol (2013) 0.91
Thyroid Papillary Microcarcinoma: Etiology, Clinical Manifestations,Diagnosis, Follow-up, Histopathology and Prognosis. Iran J Pathol (2016) 0.78
Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci (2017) 0.78
Risk Factors Associated with Disease Recurrence among Patients with Low-Risk Papillary Thyroid Cancer Treated at the University of the Philippines-Philippine General Hospital. Endocrinol Metab (Seoul) (2016) 0.76
Significance of Salivary Gland Radioiodine Retention on Post-ablation (131)I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma. Nucl Med Mol Imaging (2014) 0.75
Is familial papillary thyroid microcarcinoma more aggressive than sporadic form? Ann Surg Treat Res (2017) 0.75
A meta-analysis on the effect of operation modes on the recurrence of papillary thyroid microcarcinoma. Oncotarget (2016) 0.75
Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤2 cm: Clinicohistological Features and Prognostic Factors. Eur Thyroid J (2014) 0.75
Radioactive Iodine Ablation Decrease Recurrences in Papillary Thyroid Microcarcinoma with Lateral Lymph Node Metastasis in Chinese Patients. World J Surg (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid (2009) 2.79
Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer (2003) 2.58
The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer (1989) 2.52
Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab (2006) 2.31
Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery (2008) 2.23
Papillary microcarcinoma. World J Surg (2008) 1.96
Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg (2010) 1.86
Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol (2007) 1.77
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med (2005) 1.73
Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid (2009) 1.69
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Psychological responses to cancer recurrence. Cancer (2005) 1.34
Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid (2010) 1.32
Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg (2004) 1.26
Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol (2006) 1.26
Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol (2003) 1.25
Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid (2009) 1.16
Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract (2001) 1.13
Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol (2010) 1.13
Surviving recurrence: psychological and quality-of-life recovery. Cancer (2008) 1.08
Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol (2003) 1.06
Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab (1994) 1.05
Fear of recurrence and psychological distress in head and neck cancer patients and their carers. Psychooncology (2009) 1.04
Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg (2009) 1.04
Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab (2002) 1.03
Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery (2006) 1.02
Treatment for microcarcinoma of the thyroid--clinical experience. Clin Nucl Med (2007) 1.00
Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid (2000) 1.00
Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg (2006) 0.99
Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg (2009) 0.99
Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer Care (Engl) (2009) 0.99
Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus. Endoscopy (2010) 0.96
The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med (2007) 0.95
Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid (2006) 0.93
Differentiated thyroid cancer in a Swedish county--long-term results and quality of life. Acta Oncol (2010) 0.93
Clinical presentations and predictive variables of thyroid microcarcinoma with distant metastasis. Int Surg (1998) 0.88
The long term outcome of papillary thyroid carcinoma patients without primary central lymph node dissection: expected improvement of routine dissection. Surgery (2009) 0.87
Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope (2009) 0.86
The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life. Exp Clin Endocrinol Diabetes (2009) 0.81
Total body electrical conductivity measurements in the neonate. Clin Perinatol (1991) 0.79
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol (2004) 4.69
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med (2006) 3.20
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med (2006) 3.15
Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol (2008) 2.98
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol (2008) 2.96
Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology (2002) 2.87
Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med (2009) 2.84
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.55
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. J Nucl Med (2015) 2.47
The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer (2007) 2.30
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA (2007) 2.22
Clinical consensus statement: tracheostomy care. Otolaryngol Head Neck Surg (2012) 2.18
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. J Nucl Med (2013) 2.14
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys (2003) 2.09
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 2.05
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2009) 2.05
Practical guide to understanding the value of case reports. Otolaryngol Head Neck Surg (2008) 1.85
Progress toward a microradiation therapy small animal conformal irradiator. Med Phys (2006) 1.84
Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol (2002) 1.83
Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res (2008) 1.74
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys (2004) 1.70
A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg (2010) 1.70
Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med (2014) 1.68
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med (2008) 1.62
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol (2010) 1.55
Professional burnout among microvascular and reconstructive free-flap head and neck surgeons in the United States. Arch Otolaryngol Head Neck Surg (2010) 1.55
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2008) 1.51
Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. Mol Imaging Biol (2011) 1.49
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med (2012) 1.47
Magnitude of interfractional vaginal cuff movement: implications for external irradiation. Int J Radiat Oncol Biol Phys (2011) 1.46
Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol (2004) 1.45
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope (2010) 1.42
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys (2005) 1.39
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol (2009) 1.38
Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer (2007) 1.38
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) 1.35
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol (2005) 1.31
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg (2003) 1.28
Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging (2013) 1.26
A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys (2010) 1.26
18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med (2007) 1.25
Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg (2006) 1.24
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging (2013) 1.24
Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders. Int J Radiat Oncol Biol Phys (2010) 1.21
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol (2004) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer (2010) 1.19
An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med (2008) 1.18
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg (2007) 1.18
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler (2003) 1.16
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med (2007) 1.15
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15
The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med (2013) 1.14
Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology (2003) 1.14
Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol (2008) 1.12
Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg (2007) 1.12
Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med (2008) 1.12
Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys (2005) 1.11
The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg (2007) 1.11
Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol (2003) 1.10
Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res (2012) 1.09
The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer (2009) 1.09
Imaging in cervical cancer. Cancer (2003) 1.08
SNM practice guideline for lung scintigraphy 4.0. J Nucl Med Technol (2012) 1.06
Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope (2002) 1.05
Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol (2007) 1.05